RecruitingPhase 1NCT04038840

Imaging Synapses With [11C] UCB-J in the Human Brain

Sponsor

Davidzon, Guido, M.D.

Enrollment

60 participants

Start Date

Aug 1, 2019

Study Type

INTERVENTIONAL

Conditions

Schizophrenia

Summary

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study uses a specialized brain scan (called a PET scan with a tracer called [11C] UCB-J) to measure the number of synapses — the tiny connection points between brain cells — in living people. Researchers want to understand how synapse density changes across different brain conditions and ages. **You may be eligible if...** - You are a healthy volunteer or a patient with a neurological condition being studied (such as Alzheimer's disease or epilepsy) - You are 18 or older - You are able to lie still for a PET scan **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have conditions that prevent you from safely having a PET scan - You have a history of certain psychiatric or substance use disorders (specific criteria apply) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[11C]UCB-J radiotracer

I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein

DEVICEPET-MR

Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes

Locations(2)

VA Palo Alto Health Care System

Palo Alto, California, United States

Stanford University

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04038840

Related Trials

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT0710511122 locations

Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate

NCT063407891 location

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

NCT070612888 locations

Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.

NCT050365901 location

French Source-monitoring Task

NCT042371551 location